IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Launched by DUKE UNIVERSITY · Oct 11, 2023
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
The IMPRoving Outcomes in Vascular DisEase trial is studying a treatment approach for patients with a type of condition called Type B aortic dissection, which is a tear in the aorta that doesn’t involve certain critical areas of the heart. The trial aims to find out if a more invasive treatment called TEVAR (a procedure that helps repair the aorta) combined with medical therapy is better at preventing serious complications or death compared to a more conservative method that relies on just medication and regular check-ups.
To participate in the trial, you must be at least 21 years old, diagnosed with Stanford type B aortic dissection without any ruptures, and be within 48 hours to 6 weeks of your initial hospital visit. The trial is currently looking for participants of all genders. If you join, you’ll be monitored closely, and your doctors will work with you to follow the study’s guidelines. It’s important to know that certain conditions, like ongoing infections or significant health issues unrelated to the aorta, may prevent you from joining the study. If you’re interested, talk to your doctor to see if this trial might be right for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 21 years
- • 2. Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
- • 3. Acuity: within 48 hours - 6 weeks of index admission
- • 4. Ability to provide written informed consent and comply with the protocol
- • 5. Investigator believes anatomy is suitable for TEVAR
- Exclusion Criteria:
- • 1. Ongoing systemic infection
- • 2. Pregnant or planning to become pregnant in the next 3 months
- • 3. Life expectancy related to non-aortic conditions \< 2 years
- • 4. Unwilling or unable to comply with all study procedures including serial imaging follow-up
- • 5. Known patient history of genetic aortopathy
- • 6. Penetrating Aortic Ulcer and Intramural hematoma
- • 7. Iatrogenic (traumatic) aortic dissection
- • 8. Prior surgery for aortic dissection
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Rochester, Minnesota, United States
Kansas City, Kansas, United States
Minneapolis, Minnesota, United States
Boston, Massachusetts, United States
Brooklyn, New York, United States
Philadelphia, Pennsylvania, United States
Durham, North Carolina, United States
Birmingham, Alabama, United States
Milwaukee, Wisconsin, United States
San Francisco, California, United States
Columbus, Ohio, United States
Saint Louis, Missouri, United States
Rochester, New York, United States
Camden, New Jersey, United States
Pittsburgh, Pennsylvania, United States
Stanford, California, United States
Springfield, Illinois, United States
Seattle, Washington, United States
Detroit, Michigan, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Omaha, Nebraska, United States
Hartford, Connecticut, United States
Chapel Hill, North Carolina, United States
Stony Brook, New York, United States
Portland, Oregon, United States
Charleston, West Virginia, United States
Tampa, Florida, United States
New York, New York, United States
New Haven, Connecticut, United States
Chicago, Illinois, United States
Aurora, Colorado, United States
Norfolk, Virginia, United States
Salt Lake City, Utah, United States
Columbia, Missouri, United States
Los Angeles, California, United States
Baltimore, Maryland, United States
Syracuse, New York, United States
Worcester, Massachusetts, United States
Ann Arbor, Michigan, United States
Gainesville, Florida, United States
Indianapolis, Indiana, United States
Roslyn, New York, United States
Long Beach, California, United States
Phoenix, Arizona, United States
Scarborough, Maine, United States
Dallas, Texas, United States
Houston, Texas, United States
Newark, New Jersey, United States
Austin, Texas, United States
Plano, Texas, United States
San Diego, California, United States
Colorado Springs, Colorado, United States
Grand Rapids, Michigan, United States
Charlotte, North Carolina, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Manesh R Patel, M.D.
Principal Investigator
Duke University
Firas F Mussa, M.D.
Principal Investigator
The University of Texas at Houston
Panos Kougias, M.D.
Principal Investigator
The State University of New York at Downstate
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported